SARS-CoV-2 in inflammatory bowel disease population: Antibodies, disease and correlation with therapy

Table 1 Demographic, clinical and therapeutic characteristics of the inflammatory bowel disease cohort

Therapy	Characteristics (n, %)	Disease		Total (n)
		CD (n)	UC (n)
Biologic treatment	Male (15, 41.6)	13	3	36
	Woman (20, 55.5)	15	5
	BMI > 30 (5, 13.8)	3	2
	BMI < 30 (31, 82.2)	25	6
	Comorbidities yes (14, 38.8)	11	3
	Comorbidities no (22, 61.2)	17	5
	Age > 65 (5, 13.8)	2	3
	Age < 65 (31, 86.2)	26	5
Azathioprine	Male (9, 64.2)	3	6	14
	Woman (5, 35.7)	2	3
	BMI > 30 (1, 7.1)	1	0
	BMI < 30 (13, 92.8)	4	9
	Comorbidities yes (6, 42.8)	2	4
	Comorbidities no (8, 57.1)	3	5
	Age > 65 (3, 21.4)	1	2
	Age < 65 (11, 78.6)	4	7
Mesalazine	Male (23, 43.4)	10	13	53
	Woman (30, 56.6)	11	19
	BMI > 30 (6, 11.3)	2	4
	BMI < 30 (47, 88.7)	19	28
	Comorbidities yes (30, 56.6)	10	20
	Comorbidities no (23, 43.3)	11	12
	Age > 65 (19, 35.8)	10	9
	Age < 65 (34, 64.2)	11	23
		54	49	103

BMI: Body mass index; CD: Crohn’s disease; UC: Ulcerative colitis.

Table 2 Survey responses of 103 inflammatory bowel disease patients

Survey answers
Close contacts with positive patients (n, %)		Yes	17, 16.5
		No	85, 82.5
		Nd	1, 1
Tested for swab (n, %)		Yes	13, 12.5	Positive	1, 1
				Negative	12, 11.5
		No	90, 87.5
Symptoms (n, %)	No symptoms		49, 47.5
	Mild	Cough	19, 18.4
		Changes in taste/smell	6, 5.8
		Muscle and joint pain	12, 11.6
		Asthenia	11, 10.6
		Fever	18, 17.4
		GI symptoms	23, 22.3
	Severe	Mild dyspnea	4, 3.8
		Pneumonia	1, 0.9
Total number of patients (n)						103

GI: Gastrointestinal; Nd: Not determined.

Table 3 Severe acute respiratory syndrome coronavirus 2 IgG positive inflammatory bowel disease patients divided by presence or absence of COVID-19 symptoms and ongoing therapy

SARS-CoV-2 IgG value > 7
SARS-CoV-2 IgG positive patients (n, %)	Therapy (patients, n, %)	Disease		Total n (%)
		CD (n)	UC (n)
COVID-19 symptoms yes (12, 63.2)	Biologic drug (6, 50.0)	5	1	6
	Azathioprine (4, 33.3)	1	3	4
	Mesalazine (2, 16.6)	0	2	2
COVID-19 symptoms no (7, 36.8)	Biologic treatment (4, 57.1)	4	0	4
	Azathioprine (1, 14.3)	0	1	1
	Mesalazine (2, 28.6)	0	2	2
		12	7	19

CD: Crohn' s disease; COVID-19: Coronavirus disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; UC: Ulcerative colitis.